Pay in 4 interest-free payments of $5.97 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Tirzepatide is a dual GIP and GLP-1 receptor agonist licensed for type 2 diabetes treatment in the UK Lymphadenopathy is not listed in the Summary of Product Characteristics or reported in SURPASS or SURMOUNT clinical trials Common Mounjaro side effects are predominantly gastrointestinal, including nausea, vomiting, diarrhoea, and reduced appetite Lymph node swelling during treatment may result from infections, vaccinations, local inflammation, or other unrelated conditions Persistent, enlarging, or hard lymph nodes require GP evaluation to exclude serious underlying causes including malignancy Report any suspected adverse effects through the MHRA Yellow Card Scheme for ongoing pharmacovigilance monitoring Table of Contents Understanding Mounjaro and Its Common Side Effects Mounjaro (tirzepatide) is a prescription medication licensed in the UK for the treatment of type 2 diabetes mellitus
The authors would also like to thank Jente Schmeetz for her support
Semaglutide with B12 works by mimicking the GLP-1 hormone to improve blood sugar level regulation and decrease appetite
Our comprehensive wellness approach means were with you every step of the way
